New Two-Drug combo tested in battle against stubborn blood cancer
NCT ID NCT06948084
First seen Nov 01, 2025 · Last updated Apr 21, 2026 · Updated 32 times
Summary
This study aims to see if a new two-drug combination (daratumumab + teclistamab) works better than current standard drug combinations for people with multiple myeloma that has come back or stopped responding to their first treatment. It will enroll about 80 adults and measure how well each treatment reduces cancer cells to undetectable levels. The trial is not yet recruiting participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.